Cholestyramine
Smoldering Plasma Cell Myeloma
City of Hope Medical CenterOtherPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
29 Active assets in the Smoldering Plasma Cell Myeloma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dexasone Regeneron Pharmaceuticals | Phase 3 | BB |
Nivestim Regeneron Pharmaceuticals | Phase 3 | BB |
Lenalidomide Irene Ghobrial, MD | Phase 3 | BB |
Linvoseltamab Regeneron Pharmaceuticals | Phase 3 | BB |
Daratumumab Regeneron Pharmaceuticals | Phase 3 | BB |
View all 47 →
Same molecule, other indications
Cholestyramine is also rated in:
metabolic dysfunction-associated steatotic liver diseaseDormant
B
Indicative · Phase 2
57 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →